Swiss pharmaceutical company Roche announced net income was down but it expects mid single-digit sales increase for 2024. Roche reported that its International Financial Reporting Standards (IFRS) net income for fiscal year 2023 declined about 9% to 12.36 billion Swiss francs from 13.53 billion francs last year. But IFRS net income increased by 7% at constant exchange rates (CER) due to the increase in operating profit and lower income tax expenses. Core earnings per share was 18.57 francs down from 20.30 francs in the prior year. Annual group sales decreased 7% to 58.72 billion francs from th…